Produktinformation
- 1-Butanone, 4-[4-(4-chlorophenyl)-1,2,3,6-tetrahydro-1-pyridyl]-1-(4-fluorophenyl)-
- 1-Butanone, 4-[4-(4-chlorophenyl)-3,6-dihydro-1(2H)-pyridinyl]-1-(4-fluorophenyl)-
- 4-[4-(4-Chlorophenyl)-3,6-dihydro-1(2H)-pyridinyl]-1-(4-fluorophenyl)-1-butanone
- 4-[4-(p-Chlorophenyl)-2,5,6-trihydropyridino]-4′-fluorobutyrophenone
HPTP is a small molecule inhibitor that prevents the binding of dopamine to its receptor, which is responsible for regulating renal function. HPTP reduces glomerular filtration rate, and thus lowers blood pressure. It also has been shown to be effective in inhibiting choroidal neovascularization in rats. HPTP is a pyridinium compound that binds to dopamine receptors with high affinity and selectivity. It has been shown to inhibit the production of dopamine by human liver microsomes, but not rat liver microsomes. HPTP binds to the receptor binding site on the outside of the cell membrane and blocks access by dopamine molecules. HPTP is an analog of propranolol (a beta-blocker), which inhibits the conversion of dopamine into norepinephrine, thereby reducing blood pressure.
